Since 2011, when the United States Food and Drug Administration (U.S. FDA) approved ipilimumab (Yervoy®) for malignant melanoma, several immune-checkpoint inhibitors have been granted marketing authorisation. Do you know all the indications? MediPaper made an overview of all the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.
What is new in the management of immune-related adverse events (irAE) and other toxicities (AE)? Read our AE and irAE management blog and learn more about the latest advancements in the prevention and management of toxicities.
There is no excerpt because this is a protected post.